Literature DB >> 20566754

Cellular localization of sphingosine-1-phosphate receptor 1 expression in the human central nervous system.

Hirotake Nishimura1, Takashi Akiyama, Isao Irei, Shuji Hamazaki, Yoshito Sadahira.   

Abstract

Sphingosine-1-phosphate (S1P), a potent lipid mediator, transduces intracellular signals through the activation of S1P receptors (S1PRs). Although S1PRs have been shown to play an important role in the central nervous system (CNS), accurate localization and the function of S1PR1 in the human CNS are still unclear. In this study, we investigated the localization of S1PR1 in the human CNS of postmortem samples, using a rabbit polyclonal antibody, the specificity of which had been well defined. Immunohistochemical investigation of paraffin-embedded sections revealed diffuse granular staining of the gray matter. The signals of the gray matter were much stronger than those of the white matter. The immunohistochemical expression levels correlated well with the results of quantitative real-time RT-PCR-based analysis and Western blotting. Studies using double immunostaining and immunoelectron microscopy revealed that the antigen was strongly expressed in the membrane of the astrocytic foot processes of glia limitans and astrocytes with radial cytoplasm, but not distributed in neurons. In neurological disorders, hypertrophic astrocytes with strong expression of glial fibrillary acidic protein exhibited significantly decreased expression of S1PR1 in contrast to its strong expression in astrocytes forming fibrillary gliosis. These results indicate that S1PR1 is localized in astrocytes, and its expression level may change during the processes that occur after brain damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566754      PMCID: PMC2924800          DOI: 10.1369/jhc.2010.956409

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  39 in total

1.  Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS.

Authors:  Laura J Sim-Selley; Paulette B Goforth; Mba U Mba; Timothy L Macdonald; Kevin R Lynch; Sheldon Milstien; Sarah Spiegel; Leslie S Satin; Sandra P Welch; Dana E Selley
Journal:  J Neurochem       Date:  2009-05-31       Impact factor: 5.372

Review 2.  Heterogeneity in astrocyte morphology and physiology.

Authors:  Vitali Matyash; Helmut Kettenmann
Journal:  Brain Res Rev       Date:  2009-12-11

3.  Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma.

Authors:  Hirotake Nishimura; Takashi Akiyama; Yasumasa Monobe; Kiminori Matsubara; Yasuyuki Igarashi; Masafumi Abe; Takashi Sugihara; Yoshito Sadahira
Journal:  Mod Pathol       Date:  2010-01-15       Impact factor: 7.842

4.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

5.  Expression patterns of the lysophospholipid receptor genes during mouse early development.

Authors:  Hideyo Ohuchi; Aska Hamada; Hironao Matsuda; Akira Takagi; Masayuki Tanaka; Junken Aoki; Hiroyuki Arai; Sumihare Noji
Journal:  Dev Dyn       Date:  2008-11       Impact factor: 3.780

Review 6.  Regulation and functions of sphingosine kinases in the brain.

Authors:  Lauren Bryan; Tomasz Kordula; Sarah Spiegel; Sheldon Milstien
Journal:  Biochim Biophys Acta       Date:  2008-04-29

Review 7.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

Review 8.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

9.  Immunohistochemical detection of sphingosine-1-phosphate receptor 1 in vascular and lymphatic endothelial cells.

Authors:  Takashi Akiyama; Yoshito Sadahira; Kiminori Matsubara; Masaharu Mori; Yasuyuki Igarashi
Journal:  J Mol Histol       Date:  2008-08-29       Impact factor: 2.611

10.  Sphingosine-1-phosphate receptor 1 is a useful adjunct for distinguishing vascular neoplasms from morphological mimics.

Authors:  Takashi Akiyama; Shuji Hamazaki; Yasumasa Monobe; Hirotake Nishimura; Isao Irei; Yoshito Sadahira
Journal:  Virchows Arch       Date:  2008-11-13       Impact factor: 4.064

View more
  27 in total

1.  Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.

Authors:  Max J Hilz; Ruihao Wang; Carmen de Rojas Leal; Mao Liu; Francesca Canavese; Sankanika Roy; Katharina M Hösl; Klemens Winder; De-Hyung Lee; Ralf A Linker
Journal:  Ther Adv Neurol Disord       Date:  2017-01-06       Impact factor: 6.570

2.  A transcriptome-based assessment of the astrocytic dystrophin-associated complex in the developing human brain.

Authors:  Matthew J Simon; Charles Murchison; Jeffrey J Iliff
Journal:  J Neurosci Res       Date:  2017-05-16       Impact factor: 4.164

3.  S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.

Authors:  Pedro J Gonzalez-Cabrera; Stuart M Cahalan; Nhan Nguyen; Gor Sarkisyan; Nora B Leaf; Michael D Cameron; Tomoyuki Kago; Hugh Rosen
Journal:  Mol Pharmacol       Date:  2011-10-26       Impact factor: 4.436

4.  Ethanol triggers sphingosine 1-phosphate elevation along with neuroapoptosis in the developing mouse brain.

Authors:  Goutam Chakraborty; Mitsuo Saito; Relish Shah; Rui-Fen Mao; Csaba Vadasz; Mariko Saito
Journal:  J Neurochem       Date:  2012-04-12       Impact factor: 5.372

5.  Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.

Authors:  S Rossi; T Lo Giudice; V De Chiara; A Musella; V Studer; C Motta; G Bernardi; G Martino; R Furlan; A Martorana; D Centonze
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1.

Authors:  Hui Liu; Richard Laforest; Jiwei Gu; Zonghua Luo; Lynne A Jones; Robert J Gropler; Tammie L S Benzinger; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

7.  The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas.

Authors:  Karl Quint; Norbert Stiel; Daniel Neureiter; Hans Ulrich Schlicker; Christopher Nimsky; Matthias Ocker; Herwig Strik; Malgorzata Anna Kolodziej
Journal:  Tumour Biol       Date:  2014-06-06

8.  S1P is associated with protection in human and experimental cerebral malaria.

Authors:  Constance Am Finney; Cheryl A Hawkes; Dylan C Kain; Aggrey Dhabangi; Charles Musoke; Christine Cserti-Gazdewich; Tamas Oravecz; W Conrad Liles; Kevin C Kain
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

9.  Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents.

Authors:  Zonghua Luo; Adam J Rosenberg; Hui Liu; Junbin Han; Zhude Tu
Journal:  Eur J Med Chem       Date:  2018-03-14       Impact factor: 6.514

10.  Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.

Authors:  SunJa Kim; Jacek Bielawski; Hyunmin Yang; Yu Kong; Beiyan Zhou; Jianrong Li
Journal:  Glia       Date:  2017-11-29       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.